Xeris Biopharma (XERS) shares ended the last trading session 5.6% higher at $5.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other stocks to invest in for a stock market game. We all have heard the phrase ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

Xeris Biopharma has strong revenue growth, with net product revenue reaching $203 million in 2024 and projected to hit $255–275 million in 2025. Key products include Gvoke for severe ...

CHICAGO--(BUSINESS WIRE)--#GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...

Xeris Biopharma Holdings is listed on the CBOE trading with ticker code XERS.US. It has a market capitalisation of $903.63m, with approximately 153.94m shares in issue. Over the last year, Xeris ...